Reference is made to the stock exchange announcement from SoftOx Solutions AS on
20 July 2022 regarding the result of the European Defence Fund (EDF) application
and The Commissariat a l'Energie Atomique et aux Energies Alternatives press
release on the 6th of January 2023.
SoftOx Solutions , a medtech and clinical-stage pharmaceutical company based in
Oslo, Norway, announces the signing of the final grant agreement for the
COUNTERACT Consortium - which includes SoftOx - with the European Defence Fund.
COUNTERACT aims to reinforce the European Union's preparedness for chemical,
biological, radiological and nuclear (CBRN)-type threats. The project includes
pre-clinical and clinical studies on the safety and efficiency of medical
countermeasures targeting CBRN-type threats.
The project will cover a four-year period and started in December 2022. This
project brings together key European players: from 11 EU Member states (five
universities